- Zogenix reports positive results from sumatriptan DosePro study (Pharmaceutical Business Review)
Zogenix has announced successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache.
- Zogenix Announces Clinical Study Results for sumatriptan DosePro(TM), a Novel Migraine Treatment (Fox News)
Zogenix Announces Clinical Study Results for sumatriptan DosePro(TM), a Novel Migraine Treatment
- DR. WEIL: Get the lowdown on mountain sickness (Rocky Mountain News)
One in four people who climb to elevations 8,500 feet above sea level develop intense, throbbing headaches and other symptoms of what's often called "acute mountain sickness."
- Ask Dr. Weil: Take steps to avoid mountain sickness (Arizona Daily Star)
Q I get headaches at high altitude. Is there anything I can do to prevent them?
- NuPathe Reports Positive Phase I Results For NP101, A Novel Transdermal Patch For Acute Migraine (Medical News Today)
NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced positive Phase I results for NP101, a novel drug-device patch for acute migraine in clinical development.
- Zogenix Announces Clinical Study Results For Sumatriptan DosePro?, A Novel Migraine Treatment (Medical News Today)
Zogenix, Inc. ("Zogenix"), a private, specialty pharmaceutical company, announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the 50th Annual American Headache Society Meeting in Boston, Massachusetts.
- Dr Reddy's expects 25% growth in topline (Business Standard India)
Hyderabad-based pharma major Dr Reddy's Laboratories (DRL) expects to achieve a 25 per cent growth in its turnover during 2008-09.
- Zogenix Announces Clinical Study Results for sumatriptan DosePro(TM), a Novel Migraine Treatment (Centre Daily Times)
Zogenix, Inc. ("Zogenix"), a private, specialty pharmaceutical company, today announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the 50th Annual American Headache Society Meeting in Boston, Massachusetts.